Boon For Lupin As FDA Upgrades Somerset Site Status
Stricken US Facility Handed Voluntary Action Indicated Status By FDA
Executive Summary
Looking to provide evidence of its extended measures to improve quality, compliance and oversight, Lupin has received positive news from the FDA for its US-based manufacturing facility in Somerset, New Jersey.
You may also be interested in...
Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India
Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India
Lupin Urged To ‘Put US In Order’ As It Slides To Annual Pre-Tax Loss
Lupin’s 2021/22 financial year results revealed weakness in its core US generics business amid challenging market conditions. The Indian firm will continue to throw its weight behind its domestic business while rebuilding the US operation with more complex, high-value launches.